Source comparison
BPC-157 Ligament Tear Mechanism: Comparison
Primary Mechanism Inflammation → fibrosis → remodeling over 6–12 months COX inhibition reduces inflammation but delays fibroblast migration FAK and VEGFR2 activation accelerates fibroblast migration and angiogenesis BPC-157 addresses root mechanisms. Not sympt
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Inflammation → fibrosis → remodeling over 6–12 months
- COX inhibition reduces inflammation but delays fibroblast migration
- FAK and VEGFR2 activation accelerates fibroblast migration and angiogenesis
- BPC-157 addresses root mechanisms. Not symptom suppression
- Collagen Type I Synthesis Timeline
- Type III predominates for 6–8 weeks before Type I replacement begins
- NSAIDs may extend Type III phase by suppressing TGF-β1 signaling
- Type I collagen appears 30–40% earlier in preclinical models
- Faster Type I transition = earlier return to load-bearing activity
- Tensile Strength at 28 Days Post-Injury
- Approximately 40–50% of pre-injury strength in rat models
- 35–45% of pre-injury strength (some studies show NSAID delay)
- 65–75% of pre-injury strength in multiple rat studies
- BPC-157 shows consistent 50–80% improvement vs controls
- Angiogenesis Duration
- VEGF peaks at day 3, returns to baseline by day 5–7
- NSAIDs suppress VEGF production, reducing vascular ingrowth
- VEGF elevation sustained through day 10, greater capillary density
- Prolonged angiogenesis supports oxygen delivery to healing tissue
- Evidence Quality
- Extensive human clinical data across all ligament injuries
- Strong clinical evidence for acute pain. Mixed evidence on healing outcomes
- Robust preclinical data. Zero published human RCTs for ligaments
- Gap between animal efficacy and human validation is the core limitation
- Bottom Line for Research Use
- Baseline comparator. No intervention accelerates timeline
- May slow healing to reduce pain. Trade-off depends on goals
- Most mechanistically targeted option for ligament-specific repair research
- BPC-157 shows the strongest preclinical signal but lacks human trial data